In 2023, the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals.
Rentschler Biopharma SE, a leading contract development and manufacturing organisation (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), contributed to four, which equals nearly 25% of these biopharmaceuticals.
Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, commented: “Guiding a promising therapy from its initial clinical trials to commercialisation is a demanding endeavour that spans numerous years of development efforts."
"We provide clients with world-class solutions along the entire biopharmaceutical value chain from bioprocess development to manufacturing and regulatory support."
"These recent approvals illustrate our capability to support our client partners through this entire and challenging process, emphasising the importance of our expertise and flexibility to match unique client needs.”
Currently, Rentschler Biopharma is manufacturing a total of eight market approved biopharmaceuticals for its clients, including complex formats such as bispecific antibodies, as well as recombinant enzymes.
Rentschler Biopharma’s involvement in successfully bringing these therapeutics to the market underpins the company’s strategic role in developing innovative treatments for patients suffering from cancer, autoimmune disorders as well as rare diseases.
For the four newly approved products, Rentschler Biopharma provided support with integrated capabilities, including consulting, regulatory services, process development, technology transfer and manufacturing.
These collaborations involved international clients, showcasing the company’s global reach and excellence across its manufacturing sites.
Benedikt von Braunmühl, CEO of Rentschler Biopharma, said: “At Rentschler Biopharma, we strive to create value sustainably, together with our client partners, for patients with serious and rare diseases worldwide."
"Market approved products truly serve those patients and their caregivers by bringing them new therapeutic options. I am very grateful and proud that our company continuously makes important contributions in the development and manufacturing of innovative biopharmaceuticals and in realizing our clients’ ideas."
"My sincere gratitude goes to our cross-site teams for their integral contributions to this significant milestone and for their dedication, which is reflected in every aspect of our work.”